Pages that link to "Q51370454"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study (Q51370454):
Displaying 50 items.
- Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations (Q26749524) (← links)
- The clinical application of linagliptin in Asians (Q26781942) (← links)
- Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus (Q28066209) (← links)
- Update on the treatment of type 2 diabetes mellitus (Q28073342) (← links)
- Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants (Q28238585) (← links)
- Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis (Q28275281) (← links)
- Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials (Q28294225) (← links)
- Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. (Q30240823) (← links)
- Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years (Q30827022) (← links)
- Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis (Q30846870) (← links)
- A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. (Q33560279) (← links)
- Optimal therapy of type 2 diabetes: a controversial challenge (Q33577712) (← links)
- Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison (Q33785197) (← links)
- Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin (Q33990778) (← links)
- Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus (Q34135837) (← links)
- Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials (Q34419202) (← links)
- Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea (Q34543050) (← links)
- Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study (Q34637776) (← links)
- Clinical pharmacokinetics and pharmacodynamics of linagliptin. (Q34638128) (← links)
- Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis (Q34767965) (← links)
- Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes (Q34824247) (← links)
- Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. (Q34891146) (← links)
- Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials (Q35236019) (← links)
- Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events (Q35736564) (← links)
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme (Q35777074) (← links)
- Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus. (Q35800419) (← links)
- Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes (Q36196649) (← links)
- Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial (Q36232782) (← links)
- Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials (Q36315963) (← links)
- Triple therapy in type 2 diabetes; a systematic review and network meta-analysis (Q36361872) (← links)
- Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials (Q36401258) (← links)
- Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus (Q36428096) (← links)
- Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes (Q36520758) (← links)
- Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study (Q36560252) (← links)
- Linagliptin: A thorough Characterization beyond Its Clinical Efficacy (Q36636639) (← links)
- A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus (Q36730226) (← links)
- Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors (Q36883337) (← links)
- Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series (Q37015654) (← links)
- The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis (Q37030680) (← links)
- An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease. (Q37141607) (← links)
- Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes (Q37227407) (← links)
- Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers (Q37248403) (← links)
- Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction (Q37277960) (← links)
- Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option (Q37308941) (← links)
- Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis (Q37737474) (← links)
- A review of gliptins in 2011. (Q37965612) (← links)
- Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes (Q37965613) (← links)
- Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus (Q37982680) (← links)
- The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis (Q37984756) (← links)
- The design of the liraglutide clinical trial programme (Q37992253) (← links)